AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Gliosarcoma

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Natural Progesterone for the Treatment of Recurrent Glioblastoma Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma A Phase I/II Study of Pembrolizumab and M032 (NSC 733972) Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Pazopanib in Treating Patients With Recurrent Glioblastoma Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM Vaccine Therapy in Treating Patients With Recurrent Glioblastoma Bevacizumab Beyond Progression (BBP) Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Pembrolizumab in Treating Patients With Recurrent Glioblastoma GW572016 to Treat Recurrent Malignant Brain Tumors Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma Dose-Intense Temozolomide in Recurrent Glioblastoma Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Partial Brain Radiation Therapy, Temozolomide, Chloroquine, and Tumor Treating Fields Therapy for the Treatment of Newly Diagnosed Glioblastoma Multi-site Validation and Application of a Consensus DSC-MRI Protocol Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM Ph II Bevacizumab + Etoposide for Pts w Recurrent MG Ph I Dasatinib + Erlotinib in Recurrent MG Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma Radiosurgery Plus Bevacizumab in Glioblastoma Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme AMG 102 and Avastin for Recurrent Malignant Glioma Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma